Biodexa Pharmaceuticals Plc Files December 2024 6-K Report
Ticker: BDRX · Form: 6-K · Filed: Dec 4, 2024 · CIK: 1643918
| Field | Detail |
|---|---|
| Company | Biodexa Pharmaceuticals PLC (BDRX) |
| Form Type | 6-K |
| Filed Date | Dec 4, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, foreign-issuer, pharmaceuticals
TL;DR
Biodexa Pharma (BDXA) filed its monthly 6-K, standard foreign issuer update.
AI Summary
Biodexa Pharmaceuticals Plc (formerly Midatech Pharma Plc) filed a Form 6-K on December 4, 2024. This report is for the month of December 2024 and indicates the company is a foreign private issuer filing under the 1934 Act. The company is located in Cardiff, United Kingdom, and operates in the Pharmaceutical Preparations industry.
Why It Matters
This filing provides routine updates for investors and regulatory bodies regarding Biodexa Pharmaceuticals Plc's status as a foreign private issuer.
Risk Assessment
Risk Level: low — This filing is a routine report for a foreign private issuer and does not contain significant new financial or operational information.
Key Players & Entities
- Biodexa Pharmaceuticals Plc (company) — Registrant
- Midatech Pharma Plc (company) — Former Company Name
- 0001643918 (company) — Central Index Key
- 2834 (company) — Standard Industrial Classification
- 001-37652 (company) — SEC File Number
- 241526209 (company) — Film Number
- 44 (0)1235 888300 (company) — Business Phone
- December 4, 2024 (date) — Filing Date
FAQ
What is the primary purpose of this Form 6-K filing?
The Form 6-K is a Report of Foreign Private Issuer filed pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, for the month of December 2024.
What was Biodexa Pharmaceuticals Plc's former name?
Biodexa Pharmaceuticals Plc was formerly known as Midatech Pharma Plc, with a date of name change on June 2, 2015.
Where is Biodexa Pharmaceuticals Plc located?
The company's principal executive offices are located at 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom.
Under which SEC Act is this filing made?
This filing is made under the 1934 Act.
Does Biodexa Pharmaceuticals Plc file an annual report on Form 20-F or 40-F?
The registrant indicates it files annual reports under cover of Form 20-F.
Filing Stats: 301 words · 1 min read · ~1 pages · Grade level 17 · Accepted 2024-12-04 16:05:19
Filing Documents
- b1242446k.htm (6-K) — 11KB
- ex99_1.htm (EX-99.1) — 10KB
- biodexa_logo.jpg (GRAPHIC) — 13KB
- 0001214659-24-019955.txt ( ) — 40KB
From the Filing
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________ FORM 6-K ___________________________ REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number 001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant’s name into English) 1 Caspian Point, Caspian Way Cardiff, CF10 4DQ, United Kingdom (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x Form 40-F o Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o The information included in this Report on Form 6-K, including Exhibit 99.1, shall be deemed to be incorporated by reference into the registration statements on Form S-8 (File Number 333-209365) and Form F-3 (File Number 333 - 267932) of the Company (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this Report on Form 6-K is filed, to the extent not superseded by documents or reports subsequently filed or furnished. SUBMITTED HEREWITH Attached to the Registrant’s Form 6-K filing for the month of December 2024, and incorporated by reference herein, is: Exhibit No. Description 99.1 Press Release dated November 22, 2024. 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Biodexa Pharmaceuticals PLC Date: December 4, 2024 By: /s/ Stephen Stamp Stephen Stamp Chief Executive Officer and Chief Financial Officer 3